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Chronic inflammation is a major driving force 
for the initiation and progression of tumors in 
many tissues (Mantovani et al., 2008). For ex-
ample, in patients with ulcerative colitis (UC), 
one of the major forms of chronic inflamma-
tory bowel diseases in humans, there is an in-
creased risk of colon cancer, which is related to 
the duration, extent, and severity of inflamma-
tory disease (Rutter et al., 2004; Gupta et al., 
2007). The molecular mechanisms underlying 
this neoplastic transformation are poorly un-
derstood, but immune cells that infiltrate the 
tumor  and  produce  tumor-promoting  cyto-
kines are thought to make a major contribution 
to colon cancer growth (Mantovani et al., 2008). 
The mouse model of colitis-associated colon 
cancer (CAC), which is induced by administra-
tion of azoxymethane (AOM) followed by re-
peated  oral  administration  of  dextran  sulfate 
sodium (DSS), has been highly informative. In this   
model, neutralization of TNF (Popivanova et al., 
2008) and/or inactivation of the NF-B path-
way reduces the number and size of tumors 
(Greten et al., 2004). An additional contribu-
tion to the colon cancer cell growth is provided, 
either directly or indirectly, by cytokines involved 
in the differentiation and function of T helper 
(Th)-17 lymphocytes, such as IL-6, IL-23, and 
IL-17A (Grivennikov et al., 2009; Wu et al., 
2009). These  cytokines  activate  signal  trans-
ducer and activator of transcription 3 (STAT3) 
in tumor cells and tumor-associated inflam-
matory  cells,  enhancing  tumor  survival  and 
promoting angiogenesis (Terzic et al., 2010). 
Collectively,  these  observations  support  the 
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Chronic inflammation is a major driving force in the development of cancer in many tissues, 
but the array of factors involved in this neoplastic transformation are not well understood. 
We have investigated the role of interleukin (IL)-21 in colitis-associated colon cancer (CAC), 
as this cytokine is overexpressed in the gut mucosa of patients with ulcerative colitis (UC), a 
chronic inflammatory disease associated with colon cancer. IL-21 was increased in the gut of 
patients with UC-associated colon cancer, and in mice with CAC induced by azoxymethane 
(AOM) and dextran sulfate sodium (DSS). After AOM+DSS treatment, IL-21 KO mice showed 
reduced mucosal damage, reduced infiltration of T cells, and diminished production of IL-6 
and IL-17A. IL-21–deficient mice also developed fewer and smaller tumors compared with 
wild-type (WT) mice. Absence of IL-21 reduced signal transducer and activator of transcrip-
tion 3 activation in tumor and stromal cells. Administration of a neutralizing IL-21 antibody 
to WT mice after the last DSS cycle decreased the colonic T cell infiltrate and the production 
of IL-6 and IL-17A and reduced the number of tumors. These observations indicate that  
IL-21 amplifies an inflammatory milieu that promotes CAC, and suggest that IL-21 blockade may 
be useful in reducing the risk of UC-associated colon cancer.
© 2011 Stolfi et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months   
after the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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We  next  analyzed  the  expression  of  IL-21  in  DSS- 
induced colitis and AOM+DSS-induced CAC. In initial ex-
periments, WT mice were given 2 cycles of DSS-supplemented 
water preceded by AOM treatment, and then sacrificed at the 
end of the second DSS cycle (day 29). Analysis of IL-21 in the 
colon showed that DSS-colitis in WT mice was accompanied 
notion that distinct pathways, perhaps at different stages of   
the disease, promote CAC, and that neutralization of such path-
ways may help inhibit colitis-driven colon cancer progression.
IL-21 is a cytokine synthesized by a range of CD4+ Th cells, 
including Th1 and Th17 cells, activated NKT cells, and T fol-
licular helper cells (Monteleone et al., 2009b). IL-21 is a key 
regulator  of  the  proliferation  and/or  effector  function  of   
B cells, T cells, and natural killer cells, and also affects regulatory 
T cells (Monteleone et al., 2009b). IL-21 can also regulate the 
activity of nonimmune cells, and it plays a crucial role in many 
pathological  responses,  such  as  allergy  and  autoimmunity 
(Spolski and Leonard, 2008; Monteleone et al., 2009b). We 
have recently shown that IL-21 is overexpressed in the colonic 
mucosa of UC patients (Monteleone et al., 2005), where it 
positively regulates Th17 cell responses (Fina et al., 2008). These 
observations raise the intriguing possibility that blockade of 
IL-21 can dampen the ongoing mucosal inflammation in UC, 
thus reducing the risk of CAC. However, studies conducted in 
classical murine cancer models have shown that IL-21 inhibits, 
rather than promotes, the growth of tumors. Indeed, using a 
range of methods of IL-21 delivery, such as IL-21–transfected 
tumor cell lines, IL-21–expressing plasmids, and recombinant 
mouse IL-21, different groups have shown that IL-21 exerts 
antitumor effects both on established xenografts and dissemi-
nated tumors when used as monotherapy or in combination 
with other therapies (Skak et al., 2008). The antitumor activity 
of IL-21 is mainly mediated by NK cells and CD8+ T cells 
(Wang et al., 2003; Furukawa et al., 2006), with a requirement 
for IFN- and perforin (Ma et al., 2003; Di Carlo et al., 2004). 
IL-21 therapy is also undergoing clinical trials for metastatic 
melanoma and renal cell carcinoma (Thompson et al., 2008; 
Schmidt et al., 2010). An unanswered question, however, is 
whether the antitumor effects of IL-21 are also involved in   
inflammation-associated malignancy. If this was the case, IL-21 
inhibitors proposed for the therapy of inflammation in UC 
may compromise immune surveillance and enhance the risk of 
UC-associated colon cancer. In this study, we have tried to 
clarify the role of IL-21 in the initiation and growth of CAC.
RESULTS
Overexpression of IL-21 in human colon cancer  
and mouse CAC
First, we used immunohistochemistry to assess IL-21 expres-
sion in the mucosa of patients with UC, patients with UC- 
associated colon cancer, and normal controls. We confirmed 
the increased expression of IL-21 in UC (Fig. 1, A–C). IL-21+ 
cells were also markedly increased in the samples of UC- 
associated colon cancer patients (Fig. 1, A–C). Inflammatory 
cells and cytokines are present in the colon of patients with 
sporadic colorectal cancer, so we also analyzed IL-21 in these 
samples. A robust CD3+ cell infiltrate was present in the 
peritumoral and tumoral areas, along with a marked accumula-
tion of IL-21–producing cells (Fig. 1, B and C). More pro-
nounced  IL-21  RNA  expression  was  detected  in  tumor 
samples of patients with sporadic colorectal cancer compared 
with nontumor mucosa from the same patients (Fig. 1 D).
Figure 1.  IL-21 is overexpressed in human colon cancer. (A) IL-21 immuno-
staining in intestinal specimens from one patient with UC, one patient 
with CAC, and one healthy control (HC). The figure is representative of five 
separate experiments in which sections of five patients with UC, five patients 
with CAC, and five HCs were analyzed. Isotype control staining is indicated. 
(B) Representative immunostaining for CD3 and IL-21 in intestinal specimens 
from patients with sporadic colorectal cancer. One of five separate experi-
ments is shown. (C) Quantification of IL-21+ cells in intestinal mucosa of 
patients with UC, CAC, sporadic colorectal cancer, and HC. Data are presented 
as mean values of positive cells per high power field (hpf) ± SD of five inde-
pendent experiments in which three sections per group were analyzed. Differ-
ences were calculated using the Student’s t test. (D) RNA transcripts for IL-21 
in fresh colonic specimens taken from adjacent tumoral and nontumoral 
areas of eight patients undergoing colectomy for sporadic colorectal cancer 
were quantified by real-time PCR. Data are expressed as mean ± SD and dif-
ference was calculated using the Student’s t test.JEM Vol. 208, No. 11 
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CD4/CD8, and double-positive CD4/NK1.1 cells, whereas 
no  production  was  seen  in  CD4/CD8+  and Thy1.2high/
SCA-1+ cells (Fig. 2 C). IL-21–producing CD4+ T cells coex-
pressed mostly ROR-t and, to a lesser extent, T-bet (Fig. 2 C). 
Collectively, these data indicate that IL-21 is overexpressed in 
the colon during CAC.
IL-21 KO mice are resistant to CAC
WT and IL-21 KO mice were treated with AOM+DSS 
and monitored for tumor formation. Endoscopy on day 82 
showed that WT mice developed multiple and large tumors, 
whereas the number and size of tumors were reduced in 
by increased IL-21 (Fig. 2 A). The treatment of mice with 
AOM+DSS did not induce a significant increase in IL-21 ex-
pression compared with mice treated with DSS alone (Fig. 2 A). 
In parallel experiments, mice were treated with AOM and 
DSS and monitored for the development of tumors. At day 82, 
colonoscopy showed multiple tumors in all mice. Animals 
were sacrificed on day 84, and IL-21 expression was assessed 
in proteins extracted from tumor and nontumor samples by 
ELISA. IL-21 was significantly increased in tumor samples 
(Fig. 2 B). Flow cytometry analysis of mononuclear cells iso-
lated from colonic tumors of WT mice sacrificed at day 84 
showed that IL-21 was produced by CD4+, double-positive 
Figure 2.  Involvement of IL-21 in the 
experimental model of CAC. (A) Untreated 
mice (naive) and mice treated with AOM, DSS, 
or both were sacrificed at day 29. IL-21 pro-
tein expression was evaluated by ELISA, and 
data are expressed as pg/mg total proteins. 
Values are mean ± SEM of 4 independently 
performed experiments containing at least  
5 mice per group. (B) AOM+DSS-treated WT and 
IL-21 KO mice were sacrificed at day 84. IL-21 
protein expression was evaluated by ELISA, 
and data are expressed as pg/mg total pro-
teins. Values are mean ± SEM of four inde-
pendently performed experiments in which at 
least five mice per group were considered.  
(C) WT mice treated with AOM+DSS were 
sacrificed at day 84. Representative histo-
grams showing the percentage of IL-21+ TICs. 
IL-21+ cells were gated and then analyzed for 
the indicated markers. The example is repre-
sentative of two independent experiments in 
which cells isolated from 10 mice were analyzed. (D) Representative endoscopic pictures showing colon tumors in AOM+DSS-treated WT and IL-21 KO 
mice at day 82. Graphs show the endoscopic scoring of tumors, calculated as indicated in the Materials and methods section, and the number of lesions. 
Data indicate mean ± SEM of four experiments in which at least five mice per group were considered.
Figure 3.  IL-21 deficiency is associated with a reduction in the numbers of CD8- and DX5-expressing LPMC. Representative dot-plots show-
ing CD8+ and DX5+ cells in LPMC samples isolated from the colon of both WT and IL-21 KO mice sacrificed at day 0, at the end of the second DSS cycle 
(day 29), and at the end of the experiment (day 84). Numbers indicate the percentages of cells in the designated gates. One of three representative experi-
ments in which at least five mice per group were considered is shown.2282 IL-21 promotes colitis-associated colon cancer | Stolfi et al.
Because CD4+ T cells are involved in the growth of CAC, we 
next determined whether the diminished tumor incidence 
and severity in IL-21–deficient mice was associated with 
reduced colonic CD4+ cells. Histological evaluation showed 
that in the absence of AOM+DSS treatment, the intestine 
of  IL-21–deficient 
mice was normal and 
there was no change 
in the numbers of 
CD4+ LPMCs com-
pared with WT mice 
(unpublished  data). 
the colon of IL-21 KO mice (Fig. 2 D). These results were 
confirmed by direct assessment of tumors in mice sacrificed 
on day 84 (unpublished data).
CD4+ T cells are reduced and Foxp3-expressing T cells  
are increased in the colon of IL-21 KO mice
Lamina propria mononuclear cells (LPMCs) isolated from the 
colon of WT and IL-21–deficient mice were analyzed for 
CD8 and DX5 by flow cytometry. IL-21 deficiency was asso-
ciated with a marked reduction in CD8+ T lymphocytes and 
NK cells. This finding was evident at day 0, day 29 (after the last 
DSS cycle), and day 84 (at the end of the experiment; Fig. 3). 
Figure 4.  IL-21 KO mice exhibit milder 
colitis compared with WT mice after 
AOM+DSS treatment. (A) Shown are repre-
sentative images of H&E-stained sections 
from mice sacrificed after colitis induction 
(day 29). Photomicrographs are representative 
of four experiments in which five mice per 
group were studied. The percentages of mice 
showing various degrees of colitis are also 
indicated. (B) Representative dot plots show 
CD4+ cells in LPMCs isolated from the colon 
of WT and IL-21 KO mice sacrificed at day 29. 
Numbers indicate the percentages of cells in 
the designated gates. One of three represen-
tative experiments is shown. (C) Representa-
tive dot plots showing the percentages of 
CD4+ and/or Foxp3+ LPMCs isolated from the 
colon of WT and IL-21 KO mice sacrificed at 
day 29. The numbers indicate the percentage 
of cells in the designated quadrants. One of 
three representative experiments is shown. 
Graph shows the fraction of Foxp3+ CD4+  
T cells in LPMCs isolated from the colon of WT 
and IL-21 KO mice sacrificed at day 29. Data 
indicate mean ± SD of three independent 
experiments. In each experiment at least five 
mice per group were considered. (D) Repre-
sentative H&E (top) and immunofluorescence 
(bottom) pictures of colonic sections taken 
from IL-21 KO and WT mice at day 84 and 
stained with the indicated markers. Graph 
shows the quantification of CD4+ cells in the 
tumoral areas of IL-21 KO and WT mice. Data 
are as the mean values of positive cells per 
hpf ± SEM of four independently performed 
experiments with at least six mice per group. 
(E) Representative dot plots showing CD4+ 
cells in LPMCs isolated from colonic tumors of 
WT and IL-21 KO mice sacrificed at day 84. 
The numbers indicate the percentage of cells 
in the designated gates. One of three repre-
sentative experiments is shown. (F) Represen-
tative dot plots showing the percentages of 
CD4+ and/or Foxp3+ TICs isolated from the 
colon of WT and IL-21 KO mice sacrificed at 
day 84. The numbers indicate the percentage 
of cells in the designated quadrants. One of 
three representative experiments in which at 
least five mice per group were considered is 
shown. Graph shows the fraction of Foxp3+ 
CD4+ T cells in TICs isolated from the colon of 
WT and IL-21 KO mice sacrificed at day 84. 
Data indicate mean ± SD of three indepen-
dent experiments. In each experiment at least 
five mice per group were considered.JEM Vol. 208, No. 11 
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However, at the end of the last DSS cycle (day 29), IL-21–
deficient mice had less severe inflammation than WT mice 
(Fig. 4 A). At this time point, IL-21–deficient mice also had a 
reduced percentage of CD4+ LPMCs compared with WT mice 
(Fig. 4 B). Because IL-21 inhibits the differentiation of Foxp3-
expressing T cells (Fantini et al., 2007), we also examined the 
expression of Foxp3 in the colon of WT and IL-21 KO mice. 
IL-21–deficient mice had an increased fraction of Foxp3- 
expressing CD4 T cells at day 29 (Fig. 4 C).
To examine whether there were reduced CD4+ cells in 
tumors of IL-21–deficient mice, some animals were sacrificed   
at day 84, and tumors were excised for histology. Micros-
copic examination of hematoxylin and eosin (H&E)–stained   
colonic sections and immunofluorescence revealed mucosal 
infiltration by CD4+ cells in WT mice, but little infiltration in 
IL-21–deficient mice (Fig. 4 D). These differences were asso-
ciated with higher numbers of dysplastic glands in WT mice. 
Flow cytometry analysis of mononuclear cells isolated from 
tumoral areas confirmed that IL-21–deficient mice had a di-
minished number of CD4+ cells (Fig. 4 E), and an increased 
fraction of CD4+Foxp3+ cells (Fig. 4 F).
IL-21 KO mice produce less IL-6 and IL-17A
The contribution of CD4+ T cells, and in general of immune 
cells, in the growth of CAC is via cytokine production (Terzic   
et al., 2010), so we analyzed the cytokine profile in the colon of 
WT and IL-21 KO mice. In both types of mice, there was an 
increase  in  IL-6  and  IL-17A  transcripts  after AOM+DSS 
treatment at day 29 (Fig. 5 A). However, transcripts for IL-6 
and IL-17A were significantly lower in IL-21–deficient mice 
(Fig. 5 A). Analysis of cytokine protein by ELISA confirmed the 
reduced IL-6 and IL-17A in IL-21–deficient mice (Fig. 5 B). 
RNA transcripts and protein for IFN- were not different 
between IL-21–deficient mice and WT mice (unpublished 
data). Using real-time PCR and ELISA of samples taken from 
tumoral areas, we confirmed that lack of IL-21 was associated 
with a reduction in the expression of IL-6 and IL-17A (Fig. 5,   
C and D), whereas IFN- remained unchanged (not de-
picted). TNF expression was not different between WT and 
IL-21–deficient mice at the different time points analyzed 
(unpublished data). Flow cytometry analysis of immune cells 
isolated from colonic tumors of WT mice sacrificed at day 84 
showed that IL-6 was produced by T cells, F4/80+ cells,   
F4/80+CD206+  regulatory  macrophages,  and  CD11b+GR1+ 
cells, but not Thy1.2high/SCA-1+ cells, whereas IL-17A was 
mostly produced by T cells and, to a lesser extent, Thy1.2high/
SCA-1+ cells (Fig. 5 E). Immunofluorescence (Fig. 6 A) and flow 
cytometry (not depicted) indicated that IL-21 KO mice have a 
reduced infiltration of alternatively activated macrophages into 
the tumors as compared with WT mice. This finding was con-
firmed by the reduced expression of alternatively activated 
macrophages-related markers in tumor samples of IL-21 KO 
mice as compared with WT mice (Fig. 6 B). IL-21–deficient 
mice also showed a reduced number of tumor infiltrating   
myeloid-derived  suppressor  cells  as  compared  with WT 
mice (Fig. 6 C), paralleled by a reduction in the content of the 
immunosuppressive factor ARG1 (Fig. 6 D). In contrast, the per-
centage of Thy1.2high/SCA-1+ cells in the tumoral areas did 
not differ between WT and IL-21 KO mice (Fig. 6 E).
Overall, these findings indicate that the reduced formation 
of colonic tumors seen in IL-21–deficient mice is associated 
with a diminished infiltration of both myeloid and T cells into 
the tumor and decreased production of IL-6 and IL-17A.
STAT3 activation is reduced in IL-21 KO mice  
treated with AOM+DSS
IL-21, like IL-6 and IL-17A, is a powerful activator of the tran-
scription factor STAT3 (Caprioli et al., 2008; Hirahara et al., 
Figure 5.  IL-21 KO mice produce less IL-6 and IL-17A. (A and B) IL-6 
and IL-17A expression was assessed by real-time PCR (A) and ELISA (B) in 
colon of WT and IL-21 KO mice sacrificed at either day 0 or at day 29 after 
AOM+DSS treatment. Values are mean ± SEM of four independent experi-
ments containing at least six mice per group. (C and D) IL-6 and IL-17A 
expression were assessed by real-time PCR (C) and ELISA (D) in the colon 
of WT and IL-21 KO mice sacrificed at day 84 after AOM+DSS treatment. 
Values are mean ± SEM of four independent experiments containing at 
least six mice per group. (E) IL-6– and IL-17A–producing cells in the  
tumoral areas of WT mice treated with AOM+DSS. Representative histo-
grams showing the percentage of IL-6– and IL-17A–producing TICs. IL-6+ 
and IL-17A+ cells were gated and analyzed for the indicated markers. The 
example is representative of two independent experiments in which cells 
isolated from 10 mice were analyzed.2284 IL-21 promotes colitis-associated colon cancer | Stolfi et al.
were treated with AOM+DSS and, 1 wk later, randomized to 
receive either a neutralizing IL-21 (anti–IL-21) or control anti-
body until day 84. Endoscopy at day 82 showed that blockade 
of endogenous IL-21 significantly reduced the number of   
tumors (Fig. 8 A). Immunofluorescence of colonic tissues and 
flow cytometry of tumor-infiltrating immune cells (TICs) iso-
lated from tumoral areas of mice sacrificed at day 84 showed sig-
nificant reduction in CD4+ lymphocytes in mice given the 
anti–IL-21 antibody (Fig. 8, B and C). Moreover, anti–IL-21 
reduced IL-6 and IL-17A in tumoral samples (Fig. 8, D–E).
Immune cells but not tumor cells express IL-21R  
and respond to IL-21
Finally,  we  exam-
ined if tumor cells 
are  a  direct  target 
of IL-21. We ana-
lyzed  IL-21R  ex-
pression  in  colon 
specimens  of  WT 
mice  treated  with 
2010), which is a critical modulator of chronic inflammation 
(Atreya and Neurath, 2008). We therefore compared activation 
of STAT3 by examining phosphorylated (p)-STAT3 in colon 
tissue derived from WT and IL-21–deficient mice sacrificed on 
day 84. A higher number of p-STAT3+ cells was observed in 
WT mice compared with IL-21–deficient mice (Fig. 7 A). Cells 
positive for p-STAT3 were seen in the stroma and in the epithe-
lium of WT mice. Activation of STAT3 signaling was confirmed 
by Western blotting, with enhanced p-STAT3 immunoreactive 
bands in colonic extracts from WT mice compared with IL-21–
deficient mice (Fig. 7 B, top). Consistent with these findings,   
increased levels of the antiapoptotic protein Bcl-XL, a STAT3 
target, were detected in WT mice (Fig. 7 B, middle).
Blockade of endogenous IL-21 with a neutralizing antibody 
attenuates the progression of CAC in WT mice
The aforementioned findings suggest that elevated levels of 
IL-21 in WT mice affect the chronic phase of DSS-induced 
colitis and create a tumor-promoting inflammatory micro-
environment via increased production of IL-6 and IL-17A 
and enhanced STAT3 activation. To test this notion, WT mice 
Figure 6.  Reduced infiltration of regula-
tory macrophages and myeloid-derived 
suppressor cells in the tumors of IL-21 KO 
mice treated with AOM+DSS. (A) Represen-
tative immunofluorescence pictures of colonic 
sections taken from WT and IL-21 KO and 
stained with F4/80 and CD206 antibodies. 
Graphs show quantification of F4/80+ (top) 
and CD206+ cells (bottom) in the tumoral 
areas of WT and IL-21 KO mice sacrificed at 
day 84 after AOM+DSS treatment. Data are 
presented as mean values of positive cells per 
hpf ± SEM of four independent experiments. 
In each experiment, at least six mice per 
group were considered. (B) Fizz1, Ym1, and 
MRC1 expression was assessed by real-time 
PCR in the colonic tumors of WT and IL-21 KO 
mice sacrificed at day 84 after AOM+DSS 
treatment. Values are mean ± SEM of four 
independent experiments. In each experiment, 
at least six mice per group were considered. 
(C) Representative dot plots showing the per-
centages of Gr1 and/or CD11b+ TICs isolated 
from the colon of WT and IL-21 KO mice sac-
rificed at day 84 after AOM+DSS treatment. 
The numbers indicate the percentage of cells 
in the designated quadrants. Gr1+CD11b+ cells 
were considered as myeloid-derived suppres-
sor cells. One of two representative experi-
ments is shown. In each experiment, at least 
five mice per group were considered. (D) ARG1 
expression was assessed by real-time PCR in 
tumor samples of WT and IL-21 KO mice sac-
rificed at day 84 after AOM+DSS treatment. 
Values are mean ± SEM of four independent 
experiments in which at least six mice per 
group were considered. (E) Representative dot 
plots showing TICs isolated from the colon of 
WT and IL-21 KO mice sacrificed at day 84 
after AOM+DSS treatment and stained with 
Thy1.2 and SCA-1 antibodies. The numbers 
indicate the fraction of innate lymphoid cells 
(Thy1.2highSCA-1+) in the designated gates. 
One of two independent experiments is 
shown. In each experiment, at least five mice 
per group were considered.JEM Vol. 208, No. 11 
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Analysis  of  mechanisms  by  which  IL-21  mediates  this   
effect revealed that the lack of IL-21 was paralleled by a marked 
reduction in the number of cytotoxic lymphocytes and NK 
cells, both before and after induction of colitis. These data are 
consistent with previous studies showing that IL-21 is impor-
tant for the growth and activity of CD8+ and NK cells (Spolski 
and Leonard, 2008), and indicate that the resistance of   
IL-21–deficient  mice  against  AOM+DSS-induced  colon 
cancer is not caused by enhanced immune surveillance. In 
contrast, our data suggest that IL-21 may sustain an inflam-
matory circuit that promotes the growth of colon cancer 
during inflammation. Indeed, WT mice given a neutralizing 
IL-21 antibody exhibited markedly reduced colonic infiltra-
tion with CD4+ cells and produced less inflammatory cyto-
kines,  such  as  IL-6  and  IL-17A,  thought  to  be  master 
regulators of tumor-associated inflammation and tumorigen-
esis in the colon (Atreya and Neurath, 2008; Maniati et al., 
2010). By flow cytometry, we also showed that the majority 
of IL-6–producing cells were myeloid cells, whereas IL-17A 
was mostly produced by T cells. Because these cell types express 
IL-21R and IL-21 is produced by CD4+ cells (Monteleone   
et al., 2009b), it is conceivable that IL-21 produced in   
excess during colitis activates intracellular pathways in in-
flammatory cells in an autocrine/paracrine manner, thereby 
triggering the production of IL-6 and IL-17A with the down-
stream effect of amplifying colonic inflammation and favor-
ing carcinogenesis. Our data confirm a recent study showing 
that  innate  lymphoid  cells  (i.e.,  Thy1.2high/SCA-1+  cells) 
produce IL-17A (Buonocore et al., 2010), whereas IL-6 and 
IL-21 were not expressed by these cells types. Moreover, we 
were not able to detect IL-21R on these cells, arguing against 
the possibility that innate lymphoid cells are a target of IL-21 
in the colon. No change in the expression of IFN- and 
TNF was seen in IL-21–deficient mice, or WT mice given 
anti–IL-21. These data are somewhat different from recent 
studies where the incidence of AOM+DSS-induced colon 
cancer was markedly reduced in mice lacking TNF receptor 
p55, or in mice receiving a TNF blocker (Popivanova et al., 
2008). Interestingly, TNF did not appear to function as a 
trophic factor for epithelial cells, but was needed to activate a 
AOM+DSS and sacrificed at day 84. LPMCs and TICs 
expressed IL-21R, whereas no staining was seen in epithe-
lial cells (Fig. 9 A). Flow cytometry analysis confirmed that 
TICs, but not tumor cells, expressed IL-21R (Fig. 9 B). 
Moreover, we could not detect IL-21R in two different 
mouse  colon  cancer  cell  lines,  i.e.,  CT26  and  MC38, 
whereas IL-21R was detectable in whole colonic extracts 
(Fig. 9 C). Additional characterization of IL-21R–expressing 
TICs showed that IL-21R is broadly expressed by T and 
myeloid cells, but not Thy1.2high/SCA-1+ cells (Fig. 9 D). 
No STAT3 activation was seen in MC38 cells stimulated 
with IL-21 (Fig. 10 A).   IL-21 activated STAT3 in TICs of 
both WT and IL-21 KO mice (Fig. 10 B), but not in epi-
thelial cells isolated from the same mice (not depicted). IL-21   
increased the production of IL-6 and IL-17A via LPMCs 
isolated from the colon of both WT and IL-21 KO naive 
mice, and cultured in the presence or absence of anti-CD3 
(Fig. 10, C and D).
DISCUSSION
This study was undertaken to clarify the role of IL-21 in the 
process of colitis–induced colon carcinogenesis. Initially we 
showed up-regulation of IL-21 in the colonic mucosa of pa-
tients with UC, but also in the neoplastic areas of patients with 
UC-associated colon cancer and sporadic colorectal cancer, 
raising the possibility that IL-21 can play a major role in   
colon carcinogenesis during chronic inflammation. We then   
extended our studies using a well-accepted animal model of 
colon  cancer  (Tanaka  et  al.,  2003).  Oral  administration  of 
DSS-supplemented water to mice is a reliable model of UC, 
recapitulating some histological changes (i.e., mucosal neutro-
phil infiltration, epithelial cell loss, and ulcerations) observed in 
the colon of UC patients. Moreover, AOM treatment fol-
lowed by repeated cycles of DSS results in chronic inflamma-
tion and the development of colon tumors in nearly 100% of 
the treated mice. In the absence of IL-21, colonic inflamma-
tion was reduced, as was the tumor incidence and size. These 
results were confirmed by functional studies in WT mice that 
developed fewer and smaller tumors when given a neutralizing 
IL-21 antibody than mice treated with a control antibody.
Figure 7.  Reduced STAT3 activation in the 
tumors of IL-21 KO mice treated with 
AOM+DSS. (A) Representative immunofluores-
cence pictures of colonic sections taken from WT 
and IL-21 KO mice sacrificed at day 84 and 
stained with the indicated markers. Graph shows 
quantification of p-STAT3+ cells in the tumoral 
areas of colonic sections from WT and IL-21 KO 
mice. Data are presented as mean values of posi-
tive cells per hpf ± SD of 4 independent experi-
ments analyzing at least 5 mice per group.  
(B) Colonic tumor extracts from two WT and two 
IL-21 KO AOM+DSS-treated mice sacrificed at day 
84 were analyzed for phosphorylated STAT3 and 
BCL-XL by Western blotting. One of three repre-
sentative experiments is shown.2286 IL-21 promotes colitis-associated colon cancer | Stolfi et al.
The milder colitis and reduced CD4+ T cell infiltrate seen 
in IL-21–deficient mice may be related to the fact that the 
number of Foxp3-expressing T cells was increased in the   
colons of these mice, and that IL-21 suppresses the peripheral 
differentiation of Foxp3+ cells (Fantini et al., 2007). These 
findings may appear surprising because regulatory T cells are 
known to inhibit antitumor immune response in many tissues 
(Wolf et al., 2005; Ishibashi et al., 2006), and therefore should 
enhance rather than suppress tumorigenesis. However, it is 
noteworthy  that  regulatory T  cells  may  in  fact  be  anti-
tumorigenic in gastrointestinal cancers (Erdman et al., 2005). 
The above findings also fit with the demonstration that lack 
of IL-21 associates with reduced colonic infiltration of regu-
latory macrophages, such as alternatively activated macro-
phages and myeloid-derived suppressor cells. These data are 
not surprising as it was previously reported that IL-21 signals 
promote in vivo the differentiation of 
alternatively  activated  macrophages 
(Pesce et al., 2006) and that both alter-
natively  activated  macrophages  and 
myeloid-derived  suppressor  cells  can 
contribute to the growth of cancers in 
many organs (Sica, 2010; Greten et al., 
2011; Jinushi et al., 2011).
We also showed that IL-21–deficient   
mice exhibited a reduced activation of 
STAT3, both in the lamina propria 
and gut epithelium after AOM+DSS 
administration. This was associated with 
tumor-promoting  immune  response  (Popivanova  et  al., 
2008). Although it remains to be definitely proven, the pro-
inflammatory and tumor-promoting effects of TNF in this 
model could rely on activation of NF-B in inflammatory 
cells, because TNF is a powerful inducer of this transcription 
factor in immunocytes (Vallabhapurapu and Karin, 2009). 
There is also evidence that inactivation of NF-B in immune 
cells, but not in epithelial cells, decreases tumor size (Greten 
et al., 2004), probably as a result of a diminished production 
of cytokines that may serve as tumor growth factors. These 
findings, together with the demonstration that IL-21 is not a 
direct regulator of TNF synthesis in the AOM+DSS model 
of CAC, suggest that different, but perhaps interacting, in-
flammatory networks activated by locally released cytokines 
can contribute to ultimately promote and sustain the growth 
of colon cancer.
Figure 8.  WT mice treated weekly with 
IL-21 neutralizing antibody (anti-IL-21) 
starting from day 35 are less susceptible 
to CAC. (A) Representative endoscopic pic-
tures showing colon tumors in anti–IL-21– 
and IgG-treated AOM+DSS mice at day 82. 
Graphs show the endoscopic scoring of  
tumors (left) and the number of lesions (right) 
in anti–IL-21– and IgG-treated mice. Data are 
the mean ± SEM of a single experiment in 
which six mice per group were considered.  
(B) Representative H&E (top) and immuno-
fluorescence (bottom) images of colonic sec-
tions taken from anti–IL-21– and IgG-treated 
mice and stained with the indicated markers. 
Graphs show quantification of CD4+ cells in 
the tumoral areas of anti–IL-21– and IgG-
treated mice. (C) Representative dot plots 
showing CD4+ cells in TICs isolated from co-
lonic tumors of anti–IL-21– and IgG-treated 
mice sacrificed at day 84. Numbers indicate 
the percentage of cells in the designated 
gates. (D and E) IL-6 and IL-17A expression 
was evaluated by real-time PCR (D) and ELISA 
(E) in the colon of anti-IL-21– and IgG-
treated mice sacrificed at day 84. Values are 
mean ± SEM of a single experiment in which 
six mice per group were considered.JEM Vol. 208, No. 11 
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We were however unable to detect IL-21R in tumor 
cells of mice administered AOM+DSS, in primary colonic 
epithelial  cells  isolated  from  WT  mice  and  in  CT26  and 
MC38, two murine CC cell lines. Stimulation of both pri-
mary and tumoral epithelial cells with IL-21 did not result in 
changes in cell growth, activation of STAT3, and synthesis of 
IL-6 and IL-17A, thus suggesting that the reduced activation 
of  STAT3  in  cancer  cells  of  IL-21–deficient  mice  is  not 
caused by the lack of a direct effect of IL-21 on these cells, 
but rather could be related to the diminished 
synthesis  of  IL-6  and  IL-17A,  given  that 
these two cytokines directly activate STAT3 
reduced expression of Bcl-XL, a STAT3-induced antiapop-
totic protein. Because STAT3 activation in tumor cells and   
tumor-associated inflammatory cells plays a key role in tumor 
progression by augmenting tumor survival and angiogenesis 
and suppressing antitumor immunity (Yu et al., 2007), and   
because  active  STAT3  has  been  documented  in  CAC 
(Grivennikov et al., 2009), it is plausible that the reduced inci-
dence and size of tumors seen in IL-21–deficient mice are   
in part dependent on the diminished activation of STAT3.
Figure 9.  TICs, but not colonic epithelial 
cells, express IL-21R. (A) IL-21R immuno-
staining in colon of WT mice treated with 
AOM+DSS and sacrificed at day 84. The figure 
is representative of four separate experiments. 
(B) Representative dot plots showing the ex-
pression of IL-21R in TICs and IECs in WT mice 
treated with AOM+DSS and sacrificed at day 
84. The numbers indicate the percentages of 
IL-21R+ cells in the designated gates. One of 
three representative experiments in which at 
least five mice per group were considered is 
shown. (C) RNA transcripts for IL-21R were 
evaluated by real-time PCR in MC38 and CT26 
colon cancer cell lines. Colonic extracts from 
WT mice were used as positive control (Ve+). 
(D) Representative histograms showing the 
percentage of IL-21R+ TICs. IL-21R+ cells were 
gated and analyzed for the indicated markers 
by flow cytometry. The example is representa-
tive of two independent experiments in which 
cells isolated from 10 mice were analyzed.
Figure 10.  IL-21 activates STAT3 in TICs but 
not in epithelial cells. (A) MC38 cells were stimu-
lated with IL-21 or IL-6 or left unstimulated for  
30 min, and p-STAT3 (Y705) was assessed by flow 
cytometry. Isotype control stain is indicated. Numbers 
indicate the percentages of p-STAT3+ cells in the 
designated gates. One of three representative experi-
ments is shown. (B) TICs of both WT and IL-21 KO 
mice were stimulated or not with 50 ng/ml IL-21 for 
the indicated time points, and p-STAT3 (Y705) was 
assessed by flow cytometry. The numbers indicate the 
percentages of p-STAT3+ cells in the designated 
gates. One of three representative experiments is 
shown. (C and D) LPMCs were isolated from the colon 
of WT and IL-21 KO naive mice. Cells were cultured in 
the presence or absence of anti-CD3 (2 µg/ml) and 
stimulated or not with 50 ng/ml IL-21 for 48 h. The 
presence of IL-6 (C) and IL-17A (D) in cell culture 
supernatants was quantified by ELISA. Data are ex-
pressed as picograms/milliliter of supernatant. Values 
are mean ± SD of three independent experiments.2288 IL-21 promotes colitis-associated colon cancer | Stolfi et al.
injection, mice were given 2% DSS (mol wt, 9,000–20,000) in the drinking 
water for 4 d. 1 wk after the discontinuation of DSS administration, mice   
received a second i.p. injection of AOM (5 mg/kg). 7 d after the second 
AOM injection, mice were again given 2% DSS in the drinking water for   
4 d, followed by regular water until the end of the experiment (day 84).
Analysis of cytokine expression in the CAC model. Colonic extracts of 
both WT and IL-21 KO mice, treated or not with AOM, DSS, or both, were 
homogenized in the following lysis buffer: 10 mmol/l Hepes, pH 7.9, 1 mmol/l 
EDTA, 60 mmol/l KCl, 0.2% Igepal CA-630, 1 mmol/l sodium fluoride,   
10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mmol/l dithiothreitol, and 1 mmol/l 
PMSF. IL-21, IL-6, IL-17A, and IFN- protein expression was measured   
by ELISA according to the manufacturer’s protocol (R&D Systems).
Endoscopic procedures. For continuous monitoring of colitis and tumori-
genesis was used the Coloview high-resolution mouse endoscopic system 
(Karl-Storz; Becker et al., 2005). Tumors observed during endoscopy were 
counted to obtain the overall number of lesions. Tumor sizes of all tumors in 
a given mouse were scored using the protocol described by Becker et al. 
(2005). Tumor sizes were graded as follows: grade 1 (very small but detectable 
tumor), grade 2 (tumor covering up to one eighth of the colonic circumfer-
ence), grade 3 (tumor covering up to a quarter of the colonic circumference), 
grade 4 (tumor covering up to half of the colonic circumference), and grade 5 
(tumor covering more than half of the colonic circumference).
Histochemistry.  Histopathological  analysis  was  performed  on  colonic 
cryosections after H&E staining. The degree of inflammation at the end of 
colitis induction (day 29) was scored as absent, mild, moderate, or severe 
based on the density and extent of both the acute and the chronic inflamma-
tory infiltrate, loss of goblet cells, and bowel wall thickening. An inflamma-
tory infiltrate of low cellularity confined to the mucosa was scored as mild 
inflammation, and transmural inflammation with extension into the peri-
colonic adipose tissue with high cellularity was scored as severe. Intermediate 
changes were scored as moderate inflammation.
Immunofluorescence was performed using TSA Cy3 and fluorescein sys-
tems (Perkin Elmer) and a fluorescence microscope (BX51; Olympus) using 
primary antibodies directed against p-STAT3 (Santa Cruz Biotechnology, 
Inc.), CD4 and F4/80 (both from BD), and CD206 (AbD Serotec). The   
nuclei were counterstained with Hoechst 3342 (Invitrogen). CD4-, F4/80-, 
CD206- and p-STAT3+ cells were subsequently counted in 6–10 high 
power  fields from each slide. To assess IL-21R–expressing cells, paraffin- 
embedded colonic sections taken from WT mice undergoing AOM+DSS 
treatment and sacrificed at day 84 were stained either with anti–IL-21R anti-
body (Santa Cruz Biotechnology, Inc.) or with a control antibody (Dako).
Isolation  of  LPMCs,  TICs,  and  intestinal  epithelial  cells  (IECs). 
LPMCs and TICs were isolated as follows: entire colons from each group 
were longitudinally cut and washed with Ca+- and Mg+-free Hank’s bal-
anced salt solution (HBSS) to remove feces and debris. Tumors and tumor-
free colon pieces were finely minced and incubated in HBSS containing   
5 mM EDTA, 0.145 mg/ml dithiothreitol, 1 M Hepes (Lonza), 10% FBS, 
and 1% penicillin/streptomycin (P/S) at 37°C for 15 min for 2 cycles. EDTA 
was then removed by 3 washes in HBSS, and the tissue was digested in 
RPMI 1640 containing 0.4 mg/ml collagenase D (Roche) and 0.01 mg/ml 
DNase I (Roche) for 60 min (tumor-free colon pieces) or 45 min (tumor 
pieces) at 37°C on a shaking platform. After collagenase digestion, the me-
dium containing the mononuclear cells was collected and centrifuged at 400 g  
for 10 min and the resulting cells were resuspended in RPMI 1640 supple-
mented with 10% FBS and 1% P/S, and then used for flow cytometry 
analysis and RNA extraction. IECs were obtained by collecting the colon 
supernatants from HBSS/EDTA washings and then purified by negative se-
lection using CD45 magnetic beads (Miltenyi Biotec).
Cell cultures. The murine colon cancer cell lines MC38 and CT26 were 
cultured in DMEM and RPMI 1640 medium, respectively, both supplemented 
in tumor cells (Liu et al., 2010; Wang et al., 2009). We cannot, 
however, exclude the possibility that in patients with CAC, 
IL-21 may target directly tumor cells, as our previous study 
showed that human colonic epithelial cells, including human 
colon cancer cell lines, express IL-21R and respond to IL-21 
by up-regulating chemokine synthesis (Caruso et al., 2007).
Although data in the present study support the crucial 
role of IL-21 in the control of CAC, there is evidence indi-
cating that forced overexpression of IL-21 in tumor cells sup-
presses their growth, through enhanced antitumor immunity 
(Skak et al., 2008). Like other cytokines, IL-21 could thus 
have opposing functions on the growth of tumors, depending 
on the tissue context and the local immune activation.
In conclusion, our studies reveal for the first time the cru-
cial involvement of IL-21 in the mechanisms that control the 
incidence and ultimate growth of tumors driven by chronic 
inflammation. Given that inflammation has been implicated in 
the growth and progression of many tumors and IL-21 plays a 
pathogenic role in many chronic inflammatory processes asso-
ciated with enhanced risk of cancers (e.g., Helicobacter pylori 
gastritis and celiac disease; Monteleone et al., 2009a), the use of 
IL-21 blockers could represent an attractive and novel ap-
proach for preventing and/or treating inflammation-associated 
malignancies, as well as the underlying inflammation.
MATERIALS AND METHODS
Assessment of IL-21–producing cells in human samples. Tissue sec-
tions from 5 patients with UC, 5 patients with CAC, 5 patients with sporadic 
colon cancer, and 5 healthy controls were cut, deparaffinized, dehydrated 
through xylene and ethanol, and incubated with a rabbit anti–human IL-21 
antibody (Millipore) for 1 h at room temperature. Immunoreactive cells were 
visualized using MACH4 Universal HRP-Polymer kit with DAB (Biocare 
Medical), according to the manufacturer’s instructions, and lightly counter-
stained with hematoxylin. Isotype control sections were prepared under iden-
tical immunohistochemical conditions, replacing the primary antibody with a 
purified, normal rabbit IgG control antibody (Dako). Tissue sections of spo-
radic colorectal cancer were also stained with a monoclonal antibody against 
CD3 (Santa Cruz Biotechnology, Inc.). IL-21+ and CD3+ cells in 6–10 high-
power fields were subsequently counted in all patients. The human studies 
were approved by the ethics committee of the University of Rome Tor Ver-
gata, and each patient gave written informed consent.
Mice. WT and IL-21 KO (129S5-Il21tm1Lex) mice, both on the same genetic 
background (C57BL/6J), were purchased from Lexicon Genetics Inc. IL-21 
KO mice are viable and do not exhibit any phenotype. Mice were main-
tained in standard animal cages under specific pathogen–free conditions in 
the animal facility at the University of Rome Tor Vergata. Mice were main-
tained under a strict 12-h light cycle (lights on at 7:00 am and off at 7:00 pm), 
and given a regular chow diet (Mucedola) ad libitum. Mice were routinely 
tested (every 6 mo) for heath status and infections according to the Federa-
tion of European Laboratory Animal Science Associations (FELASA) guide-
lines. Mice resulted negative for all pathogens included in this protocol. 
Mice were also negative for the presence of Helicobacter hepaticus and Helico-
bacter bilis. WT and IL-21 KO mice were bred in heterozygous colonies and 
co-caged. Mice were genotyped and divided in separate cages at the begin-
ning of each experiment. All animal experiments were approved by the local 
Institutional Animal Care and Use Committee.
Model of CAC. All the reagents were obtained from Sigma-Aldrich unless 
specified. To induce CAC, 6–8-wk-old female WT and IL-21 KO mice re-
ceived a first i.p. injection of 10 mg/kg AOM on day 0. 7 d after the AOM JEM Vol. 208, No. 11 
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